Surface Oncology to Participate in the 2022 Wedbush PacGrow Healthcare Conference

On August 1, 2022 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Rob Ross, M.D., chief executive officer, will participate in a virtual panel discussion entitled, "IOs Wide Open – Opportunity and Challenges in Immuno-Oncology" at the 2022 Wedbush PacGrow Healthcare Conference (Press release, Surface Oncology, AUG 1, 2022, View Source [SID1234617192]). The panel discussion will take place on Tuesday, August 9, 2022, at 8:00 am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the discussion may be accessed by visiting the Investors & Media section of the Surface Oncology website at www.surfaceoncology.com. A replay of the webcast will be available on the company’s website following the presentation.